Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins

Martin Hersberger1

1Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich and Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland

Corresponding author: Martin Hersberger, Division of Clinical Chemistry and Biochemistry, University Children's Hospital, Steinwiesstr. 75, 8032 Zurich, Switzerland Phone: +41 44 266 7541, Fax: +41 44 266 7169,

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 48, Issue 8, Pages 1063–1073, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2010.212, May 2010

Publication History

Received:
2010-01-15
Accepted:
2010-02-01
Published Online:
2010-05-04

Abstract

Atherogenesis is an inflammatory process with leukocytes infiltrating the arterial intima. The lipoxygenase pathways play a role in leukocyte recruitment through the generation of two classes of arachidonic acid lipid mediators, the leukotrienes and the lipoxins, and one class of omega-3 fatty acid metabolites, the resolvins. There is evidence from animal studies and human genetic studies that the leukotrienes and the enzymes necessary for their generation play a role in atherosclerosis, and possibly even in the development of the vulnerable plaque. Less is known about the effect of the anti-inflammatory lipid mediators in atherosclerosis, the lipoxins and the resolvins. Studies modulating the activity of an enzyme necessary for the production of these lipid mediators, 12/15-lipoxygenase, showed discrepant results in several animal models. Also, human genetic studies have not clearly dissected the effect of the enzyme on atherosclerosis. However, stable forms of the lipoxins and the resolvins protect animals from inflammatory diseases. Whether blocking the leukotrienes or applying anti-inflammatory lipoxins and resolvins will be effective in attenuating human atherosclerosis needs to be demonstrated in future studies. In this review, the biosynthesis of these lipid mediators, their biological effects and the evidence for their possible role in atherosclerosis are discussed with an emphasis on human disease.

Clin Chem Lab Med 2010;48:1063–73.

Keywords: atherosclerosis; inflammation; leukotrienes; lipoxins; lipoxygenase; resolvins

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Abed Janoudi, Fadi E. Shamoun, Jagadeesh K. Kalavakunta, and George S. Abela
European Heart Journal, 2015, Page ehv653
[2]
Swathi Banthiya, Mária Pekárová, Hartmut Kuhn, and Dagmar Heydeck
Archives of Biochemistry and Biophysics, 2015
[4]
Anca D. Dobrian, David C. Lieb, Banumathi K. Cole, David A. Taylor-Fishwick, Swarup K. Chakrabarti, and Jerry L. Nadler
Progress in Lipid Research, 2011, Volume 50, Number 1, Page 115
[5]
Michel Guichardant, Catherine Calzada, Nathalie Bernoud-Hubac, Michel Lagarde, and Evelyne Véricel
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2015, Volume 1851, Number 4, Page 485
[6]
Sophia J.A. Wuest, Thomas Horn, Jacqueline Marti-Jaun, Hartmut Kühn, and Martin Hersberger
Clinical Biochemistry, 2014, Volume 47, Number 6, Page 349
[7]
Thomas Horn, Kumar Reddy Kakularam, Monika Anton, Constanze Richter, Pallu Reddanna, and Hartmut Kuhn
Redox Biology, 2013, Volume 1, Number 1, Page 566
[8]
Thomas Horn, Igor Ivanov, Almerinda Di Venere, Kumar Reddy Kakularam, Pallu Reddanna, Melanie L. Conrad, Constanze Richter, Patrick Scheerer, and Hartmut Kuhn
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013, Volume 1831, Number 12, Page 1702
[9]
Aksam J. Merched and Lawrence Chan
Current Atherosclerosis Reports, 2013, Volume 15, Number 6
[10]
Sophia J.A. Wuest, Margot Crucet, Claudio Gemperle, Christa Loretz, and Martin Hersberger
Atherosclerosis, 2012, Volume 225, Number 1, Page 121
[11]
J. Zhao, V. B. O'Donnell, S. Balzar, C. M. St. Croix, J. B. Trudeau, and S. E. Wenzel
Proceedings of the National Academy of Sciences, 2011, Volume 108, Number 34, Page 14246
[12]
Young-Chul Joo and Deok-Kun Oh
Biotechnology Advances, 2012, Volume 30, Number 6, Page 1524
[14]
Jie Zhao, Zhiyi He, Shanshan Ma, and Lei Li
Journal of Molecular Neuroscience, 2012, Volume 47, Number 3, Page 458
[15]
Gabriella Leonarduzzi, Paola Gamba, Simona Gargiulo, Fiorella Biasi, and Giuseppe Poli
Free Radical Biology and Medicine, 2012, Volume 52, Number 1, Page 19
[16]
Nhat Hao Tran Le, Karl Egil Malterud, Drissa Diallo, Berit Smestad Paulsen, Cecilie Sogn Nergård, and Helle Wangensteen
Journal of Ethnopharmacology, 2012, Volume 139, Number 3, Page 858
[17]
Vanessa Waechter, Jacqueline Marti-Jaun, Angelika Weber, Zoltan Laszlo Madi, and Martin Hersberger
Clinical Chemistry and Laboratory Medicine, 2012, Volume 50, Number 1

Comments (0)

Please log in or register to comment.